Triarco Industries Inc.

Triarco Industries Inc.
Alphastat Reduces Circulating Dihydrotestosterone (DHT) Levels in a Preliminary Clinical Trial

WAYNE, N.J.Alphastat is patented for inhibiting the enzyme 5areductase. This ultimately reduces levels of dihydrotestosterone (DHT), which has been reported for symptoms of benign prostate hyperplasia (BPH) and androgenetic alopecia. Mark L. Anderson, Ph.D., Triarcos director of research and development, will discuss the results of a preliminary three-month clinical trial showing the effect of Alphastat on DHT levels.

The VendorWorks presentation will be given Thursday, May 6, from 10 to 10:50 a.m. at SupplySide East. For additional information, visit www.triarco.com.

Share this article: Email, Slashdot, Digg, Del.icio.us, Yahoo!MyWeb, Windows Live Favorites, Furl
Add this article feed to: RSS, My Yahoo, Newsgator, Bloglines